Clinical Trials Browser

Temozolomide × Endocrine × Clear all

NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Phase 2 Active not recruiting

67 enrolled 13 charts

Somatostatinoma, Carcinoma, Neuroendocrine

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Active not recruiting

144 enrolled 15 charts

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04339036 2025-12-10

CapTemY90

Phase 2 Recruiting

Neuroendocrine Tumors

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03387592 2025-03-10

SENECA

Phase 2 Terminated

Carcinoma, Neuroendocrine

NCT05554003 2024-11-18

MeTe

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

NCT06038461 2024-10-01

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT04893785 2024-06-18

CABOTEM

Phase 2 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 15 charts

EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

Phase 2 Completed

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05647954 2022-12-13

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Phase 3 Unknown

DermatologicEndocrineNET

Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms

NCT03079440 2022-12-06

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Phase 2 Completed

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Phase 1 Terminated

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT03930771 2022-08-09

TMZ-Cap

Phase 2 Terminated

1 enrolled 8 charts

Pituitary Neoplasms

NCT04122911 2020-10-26

TENEC

Phase 2 Completed

Carcinoma, Neuroendocrine

NCT02698410 2020-10-01

ATLANT

Phase 2 Completed

40 enrolled 17 charts

Neuroendocrine Tumors

NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Phase 2 Withdrawn

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT04244708 2020-01-28

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Phase 2/3 Unknown

Pituitary Neoplasms

NCT02248012 2019-12-19

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Phase 2 Completed

Carcinoma, Neuroendocrine

NCT02231762 2019-05-06

SONNET

Phase 2 Completed

57 enrolled 20 charts

EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT03279601 2017-09-12

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Phase 2 Unknown

Neuroendocrine Tumors

NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Phase 2 Unknown

EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT01076530 2013-05-03

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Phase 1 Completed

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Paraganglioma, Extra-Adrenal, Spinal Cord Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

NCT00137774 2013-04-09

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Phase 2 Completed

Neuroendocrine Tumors

NCT00165230 2009-04-28

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Phase 2 Completed

Neuroendocrine Tumors